Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sho Wakamatsu"'
Autor:
Haruka Kishi, Isao Usui, Teruo Jojima, Shiho Fujisaka, Sho Wakamatsu, Yuiko Mizunuma-Inoue, Takafumi Niitani, Shintaro Sakurai, Toshie Iijima, Takuya Tomaru, Kazuyuki Tobe, Yoshimasa Aso
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 23; Pages: 15309
Nonalcoholic fatty liver disease (NAFLD) is an emerging worldwide health concern. The disease may involve immune cells including T cells, but little is known about the role(s) of the innate-like T cells in the liver. Furthermore, the most abundant in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa6e9994a1b21c72b2afe03e02b36823
Autor:
Toshie Iijima, Isao Usui, Yoshimasa Aso, Shintaro Sakurai, Sho Wakamatsu, Teruo Jojima, Takuya Tomaru, Masahiro Saito, Takahiko Kogai
Publikováno v:
International Journal of Cardiology. 331:243-248
Sodium/glucose cotransporter 2 (SGLT2) inhibitors decrease plasma triglyceride levels and slightly increase low-density lipoprotein (LDL-c) and high-density lipoprotein cholesterol (HDL-c). However, the mechanisms underlying such changes in the blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93217c939a51878975da0aed7659ee93
https://doi.org/10.1016/j.ijcard.2021.01.063
https://doi.org/10.1016/j.ijcard.2021.01.063
Autor:
Soichiro Hosonuma, Kazunori Yanagi, Kunihiro Suzuki, Yoshimasa Aso, Takafumi Niitani, Sho Wakamatsu, Masanori Shimizu, Masaaki Sagara
Publikováno v:
Endocrine Journal. 65:101-111
Patients with growth hormone deficiency (GHD) have an increased risk of atherosclerosis and vascular mortality. Evidence suggests that endothelial dysfunction is involved in all stages of atherogenesis. This study examined the effect of growth hormon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ee384b2dd495b2e66631dfeb648d0c0
https://doi.org/10.1507/endocrj.ej17-0330
https://doi.org/10.1507/endocrj.ej17-0330
Autor:
Kunihiro Suzuki, Yoshimasa Aso, Kazunori Yanagi, Chie Aoki, Takafumi Niitani, Masaaki Sagara, Kanako Kato, Sho Wakamatsu
Publikováno v:
Expert Opinion on Pharmacotherapy. 18:743-751
This study examined the effects of short-term administration of the sodium glucose cotransporter 2 (SGLT-2) inhibitor, dapagliflozin, on visceral fat area (VFA) in Japanese patients with type 2 diabetes.In this randomized, crossover, controlled clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15acc82bad448f065874f2a886457696
https://doi.org/10.1080/14656566.2017.1317748
https://doi.org/10.1080/14656566.2017.1317748
Autor:
Isao Usui, Yuko Maejima, Takahiko Kogai, Takuya Tomaru, Yoshimasa Aso, Masato Kase, Kenju Shimomura, Sho Wakamatsu, Toshie Iijima, Teruo Jojima
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 20, p 5237 (2019)
International Journal of Molecular Sciences
Volume 20
Issue 20
International Journal of Molecular Sciences
Volume 20
Issue 20
The aim of the present study is to investigate the effects of canagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, on non-alcoholic steatohepatitis (NASH) and NASH-related hepatocellular carcinoma (HCC) in a mouse model of di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::076f793930f11a37430165746838d119
https://www.mdpi.com/1422-0067/20/20/5237
https://www.mdpi.com/1422-0067/20/20/5237
Autor:
Kunihiro Suzuki, Kazunori Yanagi, Masanori Shimizu, Sho Wakamatsu, Takafumi Niitani, Soichiro Hosonuma, Masaaki Sagara, Yoshimasa Aso
Publikováno v:
Endocrine Journal; 2018, Vol. 65 Issue 1, p101-111, 11p